We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · February 01, 2020

Comparison of Real Costs in Newly Diagnosed Pemphigus for First-Line Rituximab vs Standard Corticosteroids

The British Journal of Dermatology


Additional Info

The British Journal of Dermatology
Comparison of Real Costs in the French Healthcare System in Newly Diagnosed Patients With Pemphigus for First-Line Treatment With Rituximab vs Standard Corticosteroid Regimen: Data From a National Multicentre Trial
Br J Dermatol 2019 Oct 28;[EPub Ahead of Print], V Hébert, T Vermeulin, L Tanguy, B Tedbirt, C Mignard, J Bénichou, P Joly

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading